1. Home
  2. HESM vs IMVT Comparison

HESM vs IMVT Comparison

Compare HESM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hess Midstream LP Share

HESM

Hess Midstream LP Share

HOLD

Current Price

$33.20

Market Cap

4.5B

Sector

Energy

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.77

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HESM
IMVT
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
5.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HESM
IMVT
Price
$33.20
$26.77
Analyst Decision
Hold
Buy
Analyst Count
9
9
Target Price
$42.25
$28.38
AVG Volume (30 Days)
1.3M
2.1M
Earning Date
01-28-2026
02-05-2026
Dividend Yield
9.05%
N/A
EPS Growth
18.64
N/A
EPS
2.81
N/A
Revenue
$1,613,000,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.89
N/A
Revenue Growth
10.78
N/A
52 Week Low
$31.63
$12.72
52 Week High
$44.14
$27.69

Technical Indicators

Market Signals
Indicator
HESM
IMVT
Relative Strength Index (RSI) 39.00 59.88
Support Level $34.20 $24.70
Resistance Level $34.82 $26.62
Average True Range (ATR) 0.49 1.07
MACD -0.14 -0.16
Stochastic Oscillator 2.42 67.06

Price Performance

Historical Comparison
HESM
IMVT

About HESM Hess Midstream LP Share

Hess Midstream LP owns, operates, develops, and acquires a diverse set of midstream assets and provides fee-based services to Hess and third-party customers. It conducts its business through three operating segments: gathering, processing and storage, and terminaling and exporting. The company derives the maximum revenue from the gathering segment. Its gathering segment consists of the following assets namely Natural Gas Gathering and Compression; Crude Oil Gathering and Produced Water Gathering and Disposal.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: